A phase I trial of DFMO targeting polyamine addiction in patients with relapsed/refractory neuroblastoma

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Sholler, Giselle L Saulnier ^a,b   Gerner, Eugene W ^c   Bergendahl, Genevieve ^a   MacArthur, Robert B ^c   VanderWerff, Alyssa ^a   Ashikaga, Takamaru ^d   Bond, Jeffrey P ^d   Ferguson, William ^e   Roberts, William ^f   Wada, Randal K ^g   Eslin, Don ^h   Kraveka, Jacqueline M ⁱ   Kaplan, Joel ^j   Mitchell, Deanna ^a   Parikh, Nehal S ^k   Neville, Kathleen ^l   Sender, Leonard ^m   Higgins, Timothy ^d   Kawakita, Masao ⁿ   Hiramatsu, Kyoko ⁿ   Moriya, Shunsuke ⁿ   Bachmann, André S ^b,o   more..

^a HELEN DEVOS CHILDREN S HOSPITAL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Cancer Prevention Pharmaceuticals   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e Cardinal Glennon Hospital   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g KAPIOLANI MEDICAL CENTER FOR WOMEN AND CHILDREN   (United States)

^h ARNOLD PALMER HOSPITAL FOR CHILDREN   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j Levine Children s Hospital   (United States)

^k Division of Pediatric Infectious Diseases   (United States)

^l CHILDREN S MERCY HOSPITAL   (United States)

^m CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

ⁿ TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^o UNIVERSITY OF HAWAII AT HILO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIACETYLSPERMINE; EFLORNITHINE; ETOPOSIDE; ORNITHINE DECARBOXYLASE; POLYAMINE; UNCLASSIFIED DRUG; ORNITHINE DECARBOXYLASE INHIBITOR;

ADOLESCENT; ALLELE; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; CONJUNCTIVITIS; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; GENE; GENE LOCUS; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; NEUROPATHY; NEUTROPENIA; ODC GENE; PAIN; PARANASAL SINUS DISEASE; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; RASH; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; URINE RETENTION; VOMITING; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; INFANT; METABOLISM; PHENOTYPE; RECURRENT DISEASE; SAFETY; URINE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EFLORNITHINE; ETOPOSIDE; FEMALE; HUMANS; INFANT; MALE; NEUROBLASTOMA; ORNITHINE DECARBOXYLASE; ORNITHINE DECARBOXYLASE INHIBITORS; PHENOTYPE; POLYAMINES; RECURRENCE; SAFETY; TREATMENT OUTCOME;

EID: 84955112641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127246     Document Type: Conference Paper

References (66)

1. Maris JM. Recent advances in neuroblastoma. The New England journal of medicine. 2010; 362 (23):2202-11. doi: 10.1056/NEJMra0804577 PMID: 20558371
2. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, et al. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatric blood & cancer. 2013; 60(6):985-93.
3. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. The New England journal of medicine. 2010; 363(14):1324-34. doi: 10.1056/NEJMoa0911123 PMID: 20879881
4. Modak S, Cheung NK. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer treatment reviews. 2010; 36(4):307-17. doi: 10.1016/j.ctrv.2010.02.006 PMID: 20227189
5. Bachmann AS. The role of polyamines in human cancer: prospects for drug combination therapies. Hawaii medical journal. 2004; 63(12):371-4. PMID: 15704548
6. Wallick CJ, Gamper I, Thorne M, Feith DJ, Takasaki KY, Wilson SM, et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene. 2005; 24(36):5606-18. PMID: 16007177
7. Koomoa DL, Yco LP, Borsics T, Wallick CJ, Bachmann AS. Ornithine Decarboxylase Inhibition by {alpha}-Difluoromethylornithine Activates Opposing Signaling Pathways via Phosphorylation of Both Akt/Protein Kinase B and p27Kip1 in Neuroblastoma. Cancer research. 2008; 68(23):9825-31. doi: 10. 1158/0008-5472.CAN-08-1865 PMID: 19047162
8. Koomoa DL, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, et al. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol. 2013; 42(4):1219-28. doi: 10.3892/ijo.2013.1835 PMID: 23440295
9. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer research. 2008; 68 (23):9735-45. doi: 10.1158/0008-5472.CAN-07-6866 PMID: 19047152
10. Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer research. 2009; 69(2):547-53. doi: 10. 1158/0008-5472.CAN-08-2968 PMID: 19147568
11. Geerts D, Koster J, Albert D, Koomoa DL, Feith DJ, Pegg AE, et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. International journal of cancer Journal international du cancer. 2010; 126 (9):2012-24. doi: 10.1002/ijc.25074 PMID: 19960435
12. Auvinen M, Paasinen A, Andersson LC, Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature. 1992; 360(6402):355-8. PMID: 1280331
13. Auvinen M, Paasinen-Sohns A, Hirai H, Andersson LC, Holtta E. Ornithine decarboxylase- and ras-induced cell transformations: reversal by protein tyrosine kinase inhibitors and role of pp130CAS. Molecular and cellular biology. 1995; 15(12):6513-25. PMID: 8524216
14. Auvinen M, Jarvinen K, Hotti A, Okkeri J, Laitinen J, Janne OA, et al. Transcriptional regulation of the ornithine decarboxylase gene by c-Myc/Max/Mad network and retinoblastoma protein interacting with c-Myc. The international journal of biochemistry & cell biology. 2003; 35(4):496-521.
15. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996; 13(4):803-12. PMID: 8761302
16. Ben-Yosef T, Yanuka O, Halle D, Benvenisty N. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene. 1998; 17(2):165-71. PMID: 9674700
17. Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer letters. 2003; 197(1-2):125-30. PMID: 12880986
18. Bachmann AS, Geerts D, Sholler G. Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. In: Hayat MA, editor. Pediatric Cancer, Neuroblastoma: Diagnosis, Therapy, and Prognosis. 1: Springer; 2012. p. 91-103.
19. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100 (13):7859-64. PMID: 12810952
20. Visvanathan K, Helzlsouer KJ, Boorman DW, Strickland PT, Hoffman SC, Comstock GW, et al. Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol. 2004; 171(2 Pt 1):652-5. PMID: 14713779
21. Brown I, Halliday S, Greig H, Heys SD, Wallace HM, Schofield AC. Genetic polymorphism in ornithine decarboxylase and risk of breast cancer. Fam Cancer. 2009; 8(4):307-11. doi: 10.1007/s10689-009-9237-9 PMID: 19225907
22. Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, et al. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res. 2009; 15(19):6208-16. doi: 10.1158/1078-0432.CCR-09-0592 PMID: 19789310
23. Norris MDG, Purgato S, Valli E, Rihani A, Van Maerken T, Vandesompele J, et al. The ornithine decarboxylase G317A polymorphism is prognostic of outcome in primary neuroblastoma and differentially affects promoter binding by the MYCN oncogene. Advances in Neuroblastoma Research. 2014;Abstract OR059:140.
24. Garcia-Huidobro JM, Brooks T, Gerner EW. Functional consequence of genetic variability in a G-quadruplex structure in the ornithine decarboxylase (odc1) gene. Nucleic Acids Research. 2014;submitted.
25. Garcia-Huidobro JT, Wertheim BC, Gerner EW. Intron 1 polymorphisms cooperate to modulate odc1 transcriptional activity and risk of colorectal adenomas. Cancer research. 2014;submitted.
26. Casero RA Jr., Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nature reviews Drug discovery. 2007; 6(5):373-90. PMID: 17464296
27. Pegg AE, Feith DJ. Polyamines and neoplastic growth. Biochemical Society transactions. 2007; 35(Pt 2):295-9. PMID: 17371264
28. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet. 2009; 374(9683):56-64. doi: 10.1016/ S0140-6736(09)61117-X PMID: 19559476
29. Alirol E, Schrumpf D, Amici Heradi J, Riedel A, de Patoul C, Quere M, et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013; 56(2):195-203.
30. Blume-Peytavi U, Hahn S. Medical treatment of hirsutism. Dermatologic therapy. 2008; 21(5):329-39. doi: 10.1111/j.1529-8019.2008.00215.x PMID: 18844711
31. Kushner BH, Kramer K, Cheung NK. Oral etoposide for refractory and relapsed neuroblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999; 17(10):3221-5.
32. Dorr RT, Liddil JD, Gerner EW. Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines. Cancer research. 1986; 46(8):3891-5. PMID: 3015379
33. Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, et al. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology. 2010; 139(3):797-805, e1. doi: 10.1053/j.gastro.2010.06.005 PMID: 20538001
34. Kawakita M, Hiramatsu K, Yanagiya M, Doi Y, Kosaka M. Determination of N(1),N(1)(2)-diacetylspermine in urine: a novel tumor marker. Methods in molecular biology. 2011; 720:367-78. doi: 10.1007/ 978-1-61779-034-8-23 PMID: 21318886
35. Kablfleisch RL. The Statistical Analysis of Failure Time Data. New York: Wiley; 1980.
36. Team RC. R: A language and environment for statistical computing. Vienna, Austria2014. Available: http://www.R-project.org/.
37. T T. -A Package for Survival Analysis in S-. R package version 2.37-7 ed2014.
38. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000. xiii, 350 p. p.
39. Harrington TR.. A class of rank test procedures for censored survival data. Biometrika 1982; 69:553-66.
40. Davison AC, Hinkley DV. Bootstrap methods and their application. Cambridge; New York, NY, USA: Cambridge University Press; 1997. x, 582 p. p.
41. Ripley ACaB. boot: Bootstrap R (S-Plus) Functions. 2015.
42. Xie X, Gillies RJ, Gerner EW. Characterization of a diamine exporter in Chinese hamster ovary cells and identification of specific polyamine substrates. J Biol Chem. 1997; 272(33):20484-9. PMID: 9252359
43. Uemura T, Yerushalmi HF, Tsaprailis G, Stringer DE, Pastorian KE, Hawel L 3rd, et al. Identification and characterization of a diamine exporter in colon epithelial cells. J Biol Chem. 2008; 283(39):26428-35. doi: 10.1074/jbc.M804714200 PMID: 18660501
44. Uemura T, Stringer DE, Blohm-Mangone KA, Gerner EW. Polyamine transport is mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2010; 299(2):G517-22. doi: 10.1152/ajpgi.00169.2010 PMID: 20522643
45. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nature Reviews Cancer. 2004; 4(10):781-92. PMID: 15510159
46. Meyskens FL Jr., McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer prevention research. 2008; 1(1):32-8. doi: 10.1158/1940-6207.CAPR-08-0042 PMID: 18841250
47. Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer prevention research. 2010; 3(1):35-47. doi: 10.1158/1940-6207.CAPR-09-0096 PMID: 20051371
48. Kareva I, Waxman DJ, Klement GL. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer letters. 2014.
49. Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatric blood & cancer. 2014; 61(4):636-42.
50. Evageliou NF, Hogarty MD. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma. Clin Cancer Res. 2009; 15(19):5956-61. doi: 10.1158/1078-0432.CCR-08-3213 PMID: 19789308
51. Gamble LD, Hogarty MD, Liu X, Ziegler DS, Marshall G, Norris MD, et al. Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. Frontiers in oncology. 2012; 2:162. doi: 10. 3389/fonc.2012.00162 PMID: 23181218
52. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nature clinical practice Oncology. 2006; 3(8):448-57. PMID: 16894390
53. Weinstein IB, Joe A. Oncogene addiction. Cancer research. 2008; 68(9):3077-80; discussion 80. doi: 10.1158/0008-5472.CAN-07-3293 PMID: 18451130
54. Choi PS, Li Y, Felsher DW. Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance. Proceedings of the National Academy of Sciences of the United States of America. 2014.
55. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nature genetics. 2013; 45(3):279-84. doi: 10.1038/ng.2529 PMID: 23334666
56. Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner EW, et al. AMXT-15, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting cell proliferation by targeting both ornithine decarboxylase and polyamine transport. International Journal of Cancer. 2013;accepted.
57. Lange I, Geerts D, Feith DJ, Mocz G, Koster J, Bachmann AS. Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation. Journal of molecular biology. 2014; 426(2):332-46. doi: 10.1016/j.jmb.2013.09.037 PMID: 24096079
58. Pendyala L, Creaven PJ, Porter CW. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1993; 2(3):235-41.
59. Carbone PP, Douglas JA, Thomas J, Tutsch K, Pomplun M, Hamielec M, et al. Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine. Clinical Cancer Research. 2000; 6 (10):3850-4. PMID: 11051229
60. Witherspoon M, Chen Q, Kopelovich L, Gross SS, Lipkin SM. Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine. Cancer discovery. 2013; 3(9):1072-81. doi: 10.1158/2159-8290.CD-12-0305 PMID: 23771434
61. Babbar N, Murray-Stewart T, Casero RA Jr. Inflammation and polyamine catabolism: the good, the bad and the ugly. Biochemical Society transactions. 2007; 35(Pt 2):300-4. PMID: 17371265
62. Soda K. The mechanisms by which polyamines accelerate tumor spread. Journal of experimental & clinical cancer research: CR. 2011; 30:95.
63. Hayes CS, Burns MR, Gilmour SK. Polyamine blockade promotes antitumor immunity. Oncoimmunology. 2014; 3(1):e27360. PMID: 24711956
64. Russell DH, Levy CC. Polyamine accumulation and biosynthesis in a mouse L1210 leukemia. Cancer research. 1971; 31(3):248-51. PMID: 5547211
65. Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, et al. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clinical Cancer Research. 2005; 11(8):2986-90. PMID: 15837752
66. Sholler GL. A Phase 1 Trial of DFMO as a Single Agent and in Combination with Etoposide in Patients with Refractory or Recurrent Neuroblastoma. Proc AACR. 2013.